Dr. Robert R. Orr, D.O.
Pulmonology (Pulmonary Disease Physician)
9171 W Thunderbird Rd, Suite 101
Peoria, AZ 85381
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- At Still University of Health Sciences, College of Osteo Med, Kirksville (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 624
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: At Still University of Health Sciences, College of Osteo Med, Kirksville
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
AZ license 2378 -
Critical Care Medicine (Internal Medicine) Physician
AZ license 2378 -
Sleep Medicine (Internal Medicine) Physician
AZ license 2378
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Banner Thunderbird Medical Center Glendale, AZ
- Banner Boswell Medical Center Sun City, AZ
Medical groups
- Phoenix Medical Group PC (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 624
- Services billed
- 3,284
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 833 | 423 |
| Test to measure expiratory airflow and volume | 338 | 242 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 251 | 235 |
| Test to determine lung volumes using sensors | 224 | 223 |
| Test to examine how well the lungs exchange gases | 206 | 205 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 74 | 40 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 68 | 63 |
| New patient office or other outpatient visit, 45-59 minutes | 63 | 63 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 52 | 17 |
| Established patient office or other outpatient visit, 20-29 minutes | 51 | 47 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Peoria, AZ | 388 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Peoria, AZ | 259 |
| Montelukast Sodium Other prescribers in Peoria, AZ | 251 |
| Prednisone Other prescribers in Peoria, AZ | 232 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Peoria, AZ | 108 |
| Fluticasone Propionate Other prescribers in Peoria, AZ | 102 |
| Advair Hfa (fluticasone propion/salmeterol) Other prescribers in Peoria, AZ | 73 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Peoria, AZ | 63 |
| Fluconazole Other prescribers in Peoria, AZ | 60 |
| Azithromycin Other prescribers in Peoria, AZ | 58 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 220 payments worth $4,310 in total to this clinician.
| GlaxoSmithKline, LLC. | $653 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $603 |
| Genzyme Corporation | $424 |
| Regeneron Healthcare Solutions, Inc. | $407 |
| Insmed, Inc. | $289 |
| Verona Pharma, Inc. | $244 |
| Electromed, Inc. | $211 |
| Baxter Healthcare | $205 |
| Food and Beverage | $4,009 |
|---|---|
| Education | $301 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. Sep 23, 2025 | Education XYWAV · NEUROLOGY · in-kind | $99.99 |
| Sanofi-aventis U.S. LLC Sep 16, 2025 | Education DUPIXENT · Immunology · in-kind | $99.99 |
| Jazz Pharmaceuticals Inc. Sep 23, 2025 | Education XYWAV · NEUROLOGY · in-kind | $67.00 |
| Amgen Inc. Sep 3, 2025 | Education in-kind | $34.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $42,211 in research payments for these studies, mostly to the institutions running them.
- Single-patient expanded access protocol for tradipitant in a single patient with gastroparesis
Vanda Pharmaceuticals Inc. - A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
Sanofi US Services Inc. · Completed · NCT06280391 - Ph IIb of Astegolimab in COPD
Genentech, Inc. - Evaluating the safety and efficacy of tradipitant vs. placebo in idiopathic and diabetic gastroparesis
Vanda Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.